Company Overview
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -87.07% |
| 6 Months: | -13.51% |
| 3 Months: | +17.24% |
| 1 Month: | -16.82% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.94 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 87.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TVGN Tevogen Inc. R2KPHARMA | 6.53 | -1.04 | $42.52M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | - | - | - | -2.32M | -2.18M | -2.33M | -29.52M | -8.60M | -6.09M | -10.36M | -5.44M | -5.73M | -5.40M |
| Net Income | -11.30K | -115 | -25.99K | 207.00K | 1.61M | -30.76M | -22.18M | -3.90M | 11.26M | -9.66M | -5.88M | -10.37M | -5.50M | -5.73M | -5.45M |
| Diluted EPS | - | - | 0.00 | - | - | -0.26 | -0.18 | -0.03 | -0.26 | -0.04 | -0.03 | -3.25 | -0.03 | -0.03 | -1.61 |
| R&D Expense | - | - | - | - | - | 1.35M | 1.03M | 1.12M | 20.81M | 4.12M | 3.26M | 3.20M | 2.70M | 3.11M | 3.13M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Income | - | -8.84M | -53.56M | -26.14M |
| Net Income | 4.41M | -60.48M | -13.73M | -26.28M |
| Diluted EPS | - | -2.44 | -3.50 | -8.08 |
| R&D Expense | - | 4.40M | 31.03M | 11.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 352.85M | 357.14M | 5.51M | 3.46M | 4.38M |
| Total Equity | 0 | -14.23M | -33.95M | -94.43M | -6.67M | -8.23M |
| Cash & Equivalents | - | 344.58K | 129.19K | 0 | 0 | 0 |
| Total Liabilities | - | 15.18M | 15.06M | 99.93M | 10.14M | 12.62M |
| Current Liabilities | - | 59.38K | 350.45K | 85.48M | 9.04M | 7.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -215.40K | -8.17M | -12.00M | -12.33M |
| Investing Cash Flow | - | -133.00K | - | -64.44K |
| Financing Cash Flow | - | 3.87M | 12.23M | 11.66M |
| Capital Expenditure | - | -133.00K | - | -64.44K |
| Free Cash Flow | - | -8.30M | - | -12.39M |
| Share Buybacks | - | 342.98M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | -13.0% | 64.0% | 205.7% | 319.1% |
| ROCE % | - | 11.1% | 959.8% | 973.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 0.15% | 23.98K | $162.56K |
| 2 | Morgan Stanley | 0.12% | 18.81K | $127.53K |
| 3 | AQR Capital Management, LLC | 0.11% | 17.24K | $116.87K |
| 4 | Goldman Sachs Group Inc | 0.09% | 14.16K | $96.03K |
| 5 | Jane Street Group, LLC | 0.07% | 11.18K | $75.77K |
| 6 | FMR, LLC | 0.06% | 9.83K | $66.62K |
| 7 | Russell Investments Group, Ltd. | 0.04% | 6.53K | $44.29K |
| 8 | Tower Research Capital LLC (TRC) | 0.01% | 1.49K | $10.13K |
| 9 | UBS Group AG | 0.01% | 1.08K | $7.34K |
| 10 | Vanguard Fiduciary Trust Co | 0.01% | 838 | $5.68K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TVGN
Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNZjA4ZXZVa3RRVlI5bWM5SkdVaWdCMndpX3JiUk1tb1lqQ2I0WXJ0MC1WaVFfLS1XSmc1VF9CMHhhZWkzUURpWldObHV0cktnMEV3bGNyYTFFZWVIdkk5MnlMOXRlUC1Eei1fN1pTZUxDTnVFV0Y5cWlTVm9TNHhkWmg5V0sza2pMN3NJ?o…
Tevogen (Nasdaq:TVGN) - Stock Analysis - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxNaE9ONldHNVhneURDSjkySEVSZ0lHSG9HVXNPWDRTYjBNWWxEV3pEeHFmT2p1ZWJJU08zSWxfMGZVRTlTaE0xX3ZRalU0RDZQZEpEbTlQUk9VdkFxejN0NlItcWN4U0JWTWNHSmVsLVhjd2hpRlRpTXh6ZHFZNDJpVQ?oc=5" target="_…
Tevogen Bio regains Nasdaq listing compliance status - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQSERVcE5zZjJuVDBXeHlHSzZFb3FiOGM5eWNSZjFaYWxnWXprZTduUm9seGlNZEc1bXYxY2YyZThnanF4VXkxUTdCVjBwbWl2amdsdTJlT3E3c2U5MHdBMkF3b2F1clhsQWlrbE11SVFQUnQ3QWZ5MFZCcmJUUDR6dmxFdExpRUdPS0R0VV…
Nasdaq issues a decision on the $50M listing requirement for Tevogen (NASDAQ: TVGN). - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPQUlVZ2JsaEE0VmQ3eGhRTEZ6empXTURSNnBValFMenpsXzlqTnJJcEI4NzhuaGdLMFVUenFtMm9jTFA5cGp2bjQxYlh6TUxrOWRRdEJGbGt2ZExPQjV0UkxaTHc0Slh0UHpQb1JuMVRRRm1CVEJXR0F3eld5ZmlLZHd5YWJYekRTelBMQz…
Tevogen Bio (TVGN) Slips 0.87% to $6.82 as Shares Test Lower End of Recent Range - Reversal Setup Alerts - https://www.siam.in/
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQSlBkUWQ2SzFjOExqZTg2TGNlaUV2X0FQVDdIQ2p3dzFmbnZGVWg4dms5UmFzUUgzY1I1X0VET1ItWVllVVNHRnJKdGxkS1ZWNzZmSWJJeUZLRkR3WXRVMzhLaFY2X0o4SjA3dGJwRXNrNTNPWjV4N2VYWjRlaDhLSUNEOXQ2cUxhWmx1Ul…
Market Movers | Winners: MMED, TVGN, PRSO | Losers: CLDI, IMG, MDCX - Trefis
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQ0ZaYmxLSF90cjJkQXRmUU9aNXpXZ281N3NCZFlkQi1rd3BrUTVLNjAzOHZraThMb2tBWlp3MXBkWkJ0ZEMwVE52dW9NNFhfQmJyZ25ESnFEMjZlTHJyQmQyMEhNMzNnT0xBZzY1bzRoa0d3WUdqV1RvX0p6WmFDbVduUFBqbFFENlNsNF…
TVGN — Frequently Asked Questions
What is the current share price of Tevogen Inc. (TVGN)?
As of 2026-10-23 16:27 PDT, Tevogen Inc. (TVGN) trades at $6.53 on NasdaqGM. Its 52-week range is $3.89 to $50.50.
What is the market capitalisation of TVGN?
Tevogen Inc. (TVGN) has a market capitalisation of $42.52M on NasdaqGM.
What is the P/E ratio of TVGN?
TVGN trades at a trailing price-to-earnings (P/E) ratio of -1.04. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -1.88.
Is TVGN a good stock to buy?
This page provides a data-driven analysis of Tevogen Inc. (TVGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.